Editorial
Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access
BMJ · 2024
DOI: 10.1136/bmj.q2254 ↗Kurz gefasst
Editorial in der Zeitschrift BMJ, 2024. Verfasst von Gavin Yamey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University. Hauptthemen laut MEDLINE: HIV Infections, Health Services Accessibility. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
HIV InfectionsHealth Services AccessibilityHumansQuinolonesAnti-HIV AgentsPre-Exposure ProphylaxisHealth Equity
Substanzen
QuinolonesAnti-HIV Agents
Autor:innen und Institutionen
- Center for Policy Impact in Global Health, Duke Global Health Institute, Duke University.
- South Africa.
Zitieren
APA
Yamey, G., & Machingaidze, S. (2024). Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access. BMJ. https://doi.org/10.1136/bmj.q2254
Vancouver
Yamey G, Machingaidze S. Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access. BMJ. 2024. doi:10.1136/bmj.q2254
BibTeX
@article{Yamey2024,
author = {Yamey, Gavin and Machingaidze, Shingai},
title = {Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access},
journal = {BMJ},
year = {2024},
doi = {10.1136/bmj.q2254}
}
EUVIMED